Metals & Mining

Sirui Advanced Materials has disclosed an announcement adjusting its industrialization project for liquid rocket engine thrust chamber materials, parts, and components. The first phase, a raised-fund project, has had its scheduled ready-for-use date postponed from December 2026 to December 2027. The investment content, total investment, implementing entity, and implementation site remain unchanged. The current investment progress is 24.67 percent, with the delay attributed to site constraints, equipment procurement, and commissioning factors. The second phase, funded by self-raised capital, has had its plan adjusted. The implementation site has been relocated from No. 12 Zhangba Seventh Road, High-tech Zone, Xi'an, Shaanxi Province, to an area south of Hengyi Road, north of Heng'er Road, east of Zongyi Road, and west of Xianhu Road in Fengxi New City, Xixian New Area, Shaanxi Province. The implementing entity has been changed from the company to its wholly owned subsidiary Shaanxi Sirui New Materials Power Technology Company Limited, while the production capacity plan remains unchanged. Due to increased supporting investment such as land acquisition and plant infrastructure at the new site, the second phase investment amount has been adjusted from the original 280 million yuan to 465 million yuan. The funding source remains self-raised capital, and the construction period has been extended from two years to four years. The project's original planned total investment was 510 million yuan, of which phase one was planned at 230 million yuan and phase two was originally planned at 280 million yuan. The company cautioned that after self-raised capital is invested, the asset scale will expand in the short term. Affected by asset dilution, return on equity may decline in the short term, and during the construction period the project will temporarily be unable to generate effective output, contributing limited profit to operations.

Caledonia Mining lowered its full-year production guidance for the Blanket mine in Zimbabwe and raised its cost outlook after third-quarter gold output fell 11% year over year to 19,106 oz. The company attributed the decline to a shortage of compressed air at certain high-grade, high-volume mining areas and the temporary retention of gold within the processing circuit, and said it expects production to normalize during the fourth quarter as two new compressors have been deployed and the last two have been released from port and are being transported to the mine. For fiscal 2026, Caledonia cut Blanket production guidance to a range of 69,000-72,500 oz from a previous outlook of 72,000-76,500 oz, implying fourth-quarter production at Blanket of 19,800-23,300 oz. Reflecting the lower expected volumes, the company raised full-year on-mine cost guidance to $1,700-$1,900 per oz sold from a prior view of $1,600-$1,800 per oz sold, and hiked all-in sustaining cost guidance to $2,650-$2,850 per oz sold from an earlier forecast of $2,500-$2,700 AISC. CEO Mark Learmonth said that although guidance for 2026 has been revised to reflect the third-quarter performance, Blanket remains a robust and cash-generative operation. Shares fell 2.6% in Friday's trading.

Caledonia Mining Corporation Plc reported gold production of 17,030 ounces from its Blanket Mine in Zimbabwe for the quarter ended September 30, 2026, down from 19,106 ounces a year earlier, and cut its full-year 2026 production guidance to a range of 69,000 to 72,500 ounces from a previous range of 72,000 to 76,500 ounces. The company said the quarter was hurt by a shortage of compressed air at certain high-grade, high-volume mining areas and a temporary increase in gold inventory in the metallurgical plant, with delays in delivering and deploying four new compressors severely affecting output at deeper 30 and 34 levels. Two of the new compressors are now deployed and the last two have been released from port and are being transported to the mine, so Caledonia expects normalised production in the fourth quarter, which it guides to approximately 19,800 to 23,300 ounces. Alongside the production cut, on-mine cost per ounce sold was revised to US$1,700 to US$1,900 from US$1,600 to US$1,800, all-in sustaining cost guidance was revised to US$2,650 to US$2,850 per ounce sold from US$2,500 to US$2,700, and group capital expenditure guidance for FY 2026 was reduced to US$94.3 million from US$103.3 million, reflecting timing of expenditures only, primarily components of the 132kV power line project now expected in 2027. Chief Executive Officer Mark Learmonth said Blanket remains a robust and cash-generative operation and that the measures support plans for more consistent production, improved grade and lower unit costs in 2027.

Fosun Group has put part of its stake in Hainan Mining on the trading table, marking its fifth sale of listed company assets this year to raise funds. Hainan Mining announced on the evening of October 9 that its controlling shareholder, Shanghai Fosun High Technology Group, plans to transfer 99.2255 million shares, approximately 5% of the total share capital, to Changxing Xinhua Commercial Operation, a state-owned platform in Changxing County, through a negotiated transfer at 9.08 yuan per share, with a total consideration of approximately 901 million yuan. Before this equity change, Fosun High Technology held 949 million shares of Hainan Mining, a 47.82% stake; after the transfer, its holding will drop to 849 million shares, or 42.82%, remaining the controlling shareholder, with Guo Guangchang still the actual controller. The transferee, Changxing Xinhua, is a wholly owned subsidiary of Changxing County Chengxi Construction Development Group. The transaction has been approved by the state-owned assets regulator of Changxing County, and the transferred shares will be subject to a 12-month lock-up period after registration. Fosun High Technology said the transfer is mainly based on its own operational funding needs and aims to promote collaboration between Hainan Mining and Changxing state-owned assets in the new energy industry, with no clear plans for further increases or reductions in the next 12 months.

Northern Rare Earth announced that its rare earth concentrate trading price for the fourth quarter of 2026 has been adjusted to 38,769 yuan per tonne, excluding tax, on a dry basis, with REO equal to 50 percent. The pricing is based on the rare earth concentrate pricing method and the rare earth oxide prices calculated for the third quarter of 2026, and was approved at the company's 20th general manager's office meeting in 2026. The announcement also clarified that for every 1 percent increase or decrease in REO, the tax-exclusive price will correspondingly increase or decrease by 775.38 yuan per tonne.

Guangzheng Eye Hospital announced on the evening of October 8 that its subsidiary, Shanghai New Vision Eye Hospital Co., Ltd., received an Administrative Penalty Decision from the Shanghai Municipal Medical Security Bureau. The hospital was fined 1.0456 million yuan for including medical expenses that did not fall within the payment scope of the medical security fund in medical insurance settlements, causing losses to the fund. Guangzheng Eye Hospital stated that the penalty will affect its 2026 operating results, with the final actual impact amount subject to the annual audit results. Rectification work at the subsidiary hospital has been fully completed and will not have a significant impact on the company's long-term development. The announcement noted that the company and its controlling subsidiaries have accumulated administrative penalties totaling 1.9712 million yuan over the past 12 consecutive months, accounting for 10.11% of the company's most recent audited net profit attributable to the parent. All fines have been paid and recorded in current profit and loss.

Guangzheng Eye Care disclosed in an announcement on the evening of October 8 that its subsidiary Shanghai New Vision Eye Hospital Co., Ltd. recently received an Administrative Penalty Decision from the Shanghai Municipal Medical Security Bureau. The bureau's investigation found that during medical insurance settlement, the hospital included medical expenses outside the scope payable by the medical security fund, causing losses to the fund. Pursuant to Article 38 of the Regulations on the Supervision and Administration of the Use of Medical Security Funds, the Shanghai Municipal Medical Security Bureau imposed an administrative penalty on Shanghai New Vision Eye Hospital Co., Ltd., with a fine of about 1.0456 million yuan. Guangzheng Eye Care stated that the penalty will affect the company's 2026 operating results, and that the subsidiary hospital has completed rectification. The penalty will not have a material impact on the company's long-term development.

Guangzheng Eye Hospital announced after market close on October 8 that its subsidiary Shanghai New Vision Eye Hospital Co., Ltd. received an administrative penalty decision from the Shanghai Municipal Medical Security Bureau. For including medical expenses that did not fall within the payment scope of the medical security fund in its settlements, causing losses to the fund, it was fined RMB 1.0456 million. The announcement showed that the conduct fell under item 6 of Article 38 of the Regulations on the Supervision and Administration of the Use of Medical Security Funds. As of the disclosure date, Guangzheng Eye Hospital and its controlled subsidiaries had accumulated administrative penalties totaling RMB 1.9712 million over the preceding 12 consecutive months, accounting for 10.11% of the company's most recent audited net profit attributable to the parent. All fines have been paid and recorded in current profit or loss. The company said the penalty will affect operating results for 2026, with the final actual impact subject to the annual audit by its accounting firm, but it will not have a material impact on long-term development and does not trigger mandatory delisting for major violations. The subsidiary hospital has completed special rectification as required, including organizing study of the relevant regulations and medical insurance service agreements, assigning dedicated personnel for medical insurance management, improving oversight procedures, and establishing accountability mechanisms.

Guangzheng Eye Hospital Group Co., Ltd. announced that its subsidiary Shanghai New Vision Eye Hospital Co., Ltd. received an administrative penalty decision from the Shanghai Municipal Healthcare Security Bureau, imposing a fine of 1.0456 million yuan. An investigation by the Shanghai Municipal Healthcare Security Bureau found that during medical insurance settlement, the hospital included medical expenses outside the scope payable by the healthcare security fund, causing losses to the fund and violating relevant provisions of the Regulations on the Supervision and Administration of the Use of Healthcare Security Funds. Under Article 38 of the regulations, designated medical institutions that engage in such conduct and cause fund losses shall be ordered to return the funds and fined between one and two times the amount of the loss. Guangzheng Eye Hospital stated that the subsidiary hospital has carried out special rectification as required, including organizing medical staff to study the relevant regulations and medical insurance service agreements, inviting medical insurance experts to conduct policy training, assigning dedicated personnel for medical insurance management, improving medical insurance supervision procedures, and establishing accountability mechanisms. The relevant rectification work has now been fully completed. Financial reports show that in the first half of 2026, Guangzheng Eye Hospital achieved operating revenue of 390 million yuan, down 10.55 percent year on year; net profit attributable to shareholders of the listed company was 17.7758 million yuan, up 1,152.76 percent year on year; and net profit after deducting non-recurring gains and losses was negative 3.2317 million yuan. Medical industry revenue was 369 million yuan, accounting for 94.70 percent of operating revenue.

Guangzheng Eye Hospital announced on October 8 that its subsidiary, Shanghai New Vision Eye Hospital Co., Ltd., was fined 1.05 million yuan by the Shanghai Municipal Medical Security Bureau for including medical expenses outside the scope of medical security fund payments in settlements, causing losses to the medical security fund. The company and its controlled subsidiaries have accumulated administrative penalties totaling 1.9712 million yuan over the past 12 consecutive months, accounting for 10.11% of the company's most recent audited net profit attributable to the parent. The fines have been fully paid and recorded in current period profit and loss. In the first half of 2026, Guangzheng Eye Hospital achieved revenue of 390 million yuan and net profit attributable to the parent of 17.78 million yuan.